Mesa Laboratories Inc (MLAB)

Featured in Small-Cap Stocks

Mesa Laboratories, Inc. is a Lakewood, Colorado-based company incorporated in 1982 and listed on NASDAQ under the ticker MLAB. The company develops, manufactures, sells, and services life sciences tools and quality control products used in healthcare, pharmaceutical, medical device, laboratory, and related industrial settings across North America, Europe, the Asia Pacific, and other international markets.

Its operations are organized into several segments. Sterilization and Disinfection Control provides biological, chemical, and cleaning indicators, along with testing and laboratory services, to help evaluate sterilization, disinfection, and cleaning processes. Clinical Genomics offers the MassARRAY genetic analysis system and related consumables for applications including inherited disease testing, pharmacogenetics, oncology, infectious disease, and research use. Biopharmaceutical Development supplies automated protein-analysis systems, peptide synthesis instruments, and peptide purification products. Calibration Solutions provides measurement and calibration products for environmental and process monitoring, dialysis, gas flow, air quality, and torque testing under brands such as DialyGuard, ViewPoint, DataTrace, DryCal, and BGI.


Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-MLAB
$105.04
7.7% Upside
Fair
$112
14.8% Upside
Fair
Good
August 31, 2026
September 15, 2026
0.64
0.7%
August 12, 2026
80.7x
2.9x
2.2x
534.1 M
682 M
24.0%
87.9%
2.0
52.5%
589.7%
Valuation • Fair Value

Mesa Laboratories Inc (NASDAQ-MLAB) Fair Value by Valuation Model

Compare the primary fair value estimate for Mesa Laboratories Inc (NASDAQ-MLAB) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$105.04

Estimated upside of 7.7% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$13.48

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$105.04

Comparable-company valuation reference.

Analyst Price Target

$112

Analysts imply upside of 14.8%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Mesa Laboratories Inc (NASDAQ-MLAB) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Mesa Laboratories Inc (NASDAQ-MLAB)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

249.1 M

Current operating scale indicator.

Revenue Forecast

259.5 M

Forward revenue estimate.

EBITDA

41.782 M

Current operating profitability reference.

EBITDA Forecast

63.2 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Mesa Laboratories Inc (NASDAQ-MLAB) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Mesa Laboratories Inc (NASDAQ-MLAB)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

8

Relatively strong quality score.

Beneish M-Score

-2.72

No elevated caution signal from this screen.

Altman Z-Score

2.0

Intermediate risk zone.

FCF / Net Income

589.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Mesa Laboratories Inc (NASDAQ-MLAB). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Mesa Laboratories Inc (NASDAQ-MLAB)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 12, 2026

Days to Earnings

22

Dividend Payment Date

September 15, 2026

Ex-Dividend Date

August 31, 2026

Dividend Yield

0.7%

Income yield reference.

Upcoming Dividend

0.64

Upcoming distribution amount.

Payment Type

Cash

Distribution type as reported in the data.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

52.5%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Mesa Laboratories Inc (NASDAQ-MLAB), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Mesa Laboratories Inc (NASDAQ-MLAB) Stock Forecast & Technical Outlook

Review Mesa Laboratories Inc (NASDAQ-MLAB) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Mesa Laboratories Inc (NASDAQ-MLAB) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Mesa Laboratories Inc (NASDAQ-MLAB) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Mesa Laboratories Inc (NASDAQ-MLAB) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Mesa Laboratories Inc (NASDAQ-MLAB) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Buy

The monthly technical read for Mesa Laboratories Inc (NASDAQ-MLAB) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Mesa Laboratories Inc (NASDAQ-MLAB)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Mesa Laboratories Inc (NASDAQ-MLAB) has a Hold consensus, with 1 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 2
Sell 0
FAQ Fast Investor Answers

Mesa Laboratories Inc (NASDAQ-MLAB) Stock FAQ

Quick answers about Mesa Laboratories Inc (NASDAQ-MLAB) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$105.04
Estimated upside 7.7%
Valuation Rating
Undervalued
Estimated upside of 7.7%
Analyst Target
$112
Implied upside 14.8%
Financial Health
Good
Current financial-health read

The current fair value estimate for Mesa Laboratories Inc (NASDAQ-MLAB) is $105.04. This implies an estimated upside of 7.7% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 7.7% versus the current market price.

The available analyst price target for Mesa Laboratories Inc (NASDAQ-MLAB) is $112. The analyst target implies estimated upside of 14.8%.

The current financial health read for Mesa Laboratories Inc (NASDAQ-MLAB) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Mesa Laboratories Inc (NASDAQ-MLAB) is August 12, 2026.

Based on the current data, dividend yield is 0.7%, upcoming dividend amount is 0.64, ex-dividend date is August 31, 2026, payment date is September 15, 2026.

The current P/E ratio listed for Mesa Laboratories Inc (NASDAQ-MLAB) is 80.7x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Mesa Laboratories Inc is 534.1 M.

The current enterprise value listed for Mesa Laboratories Inc is 682 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Mesa Laboratories Inc is NASDAQ-MLAB, and the stock is listed on NASDAQ.

Mesa Laboratories Inc (NASDAQ-MLAB) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Mesa Laboratories Inc is 24.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Mesa Laboratories Inc is 87.9%. Free float helps investors understand how much of the share base is available for public trading.